XClinical to Present and Exhibit at Upcoming CDISC Interchange in Tokyo
XClinical jointly exhibits with its Japanese CRO partner Asklep at the CDISC Japan Interchange. XClinical has been selected for an ODM training course and for a presentation in the area “Vendor Applications and Tools.”
Munich, Germany-May 26, 2008-XClinical (www.xclinical.com), a European vendor of innovative software products for eClinical trials and known for its innovative and user-friendly CDISC ODM certified EDC software suite MARVIN, today announced its comprehensive participation at the CDISC Interchange in Tokyo, Japan.
The exhibition will take place jointly with Asklep (www.asklep.co.jp), the company’s Japanese customer: “Asklep is the first Japanese CRO to join CDISC, and having a CDISC ODM certified partner like XClinical certainly speeds up our goal for having a global standard EDC solution for our clients here in Japan” said Toshio Yoshii, PhD, director of clinical information division at Asklep.
XClinical executives will be involved in both CDISC presentations and training sessions. Dr. Claus Lindenau, XClinical’s head of business development, will present a lecture entitled "End To End Processing-A presentation of CDISC certified tools and their benefits in clinical research." The presentation will emphasize how the process from study design via data capture to submission and archival can profit from using a combination of CDISC based software solutions.
Dr. Philippe Verplancke, XClinical’s chief executive officer, will lead the ODM training course on Tuesday, June 3. The training provides an in-depth understanding of the CDISC standards, ODM, and define.xml and how the underlying XML technology can support the complete clinical data management process from CRF design to submission.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
